Clinical Trials

Breast Neoplasms

NCT00424164 2024-03-08

LAPATAM

20 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

65 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02650752 2021-01-26

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Breast Neoplasms, Neoplasm Metastasis

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

31 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

13 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT01434303 2019-05-20

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

37 enrolled

Breast Neoplasms

NCT02073916 2019-04-16

STELA

24 enrolled

Breast Neoplasms

NCT00371488 2018-08-31

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Breast Neoplasms

NCT00462956 2018-08-31

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

59 enrolled

Breast Neoplasms

NCT00790816 2018-02-28

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

500 enrolled

Breast Neoplasms, Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

52 enrolled

Breast Neoplasms, Neoplasms

NCT00258050 2017-12-06

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

24 enrolled

Breast Neoplasms

NCT00169533 2017-11-17

Rollover Study Of Lapatinib In Cancer Patients

31 enrolled

Breast Neoplasms

NCT00388076 2017-11-17

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

86 enrolled

Breast Neoplasms

NCT00650910 2017-11-17

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

17 enrolled

Breast Neoplasms

NCT00849329 2017-11-14

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

12 enrolled

Breast Neoplasms

NCT00359190 2017-11-13

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

28 enrolled

Breast Neoplasms

NCT00821054 2017-11-13

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

24 enrolled

Breast Neoplasms

NCT00996762 2017-11-13

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

158 enrolled

Breast Neoplasms

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

13 enrolled 13 charts

Breast Neoplasms

NCT00753207 2016-02-15

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

10 enrolled

Breast Neoplasms

NCT02131506 2016-02-02

CAELYX

Breast Neoplasms

NCT00632489 2015-06-08

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

20 enrolled 5 charts

Breast Neoplasms, Neoplasms

NCT01238029 2014-11-21

CELAVIE

12 enrolled

Breast Neoplasms

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

28 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00544804 2014-07-02

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

41 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00513058 2014-01-14

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT00316875 2013-11-08

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

23 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

60 enrolled

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT00614978 2012-09-19

LAPTEM

18 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01133912 2012-01-04

PGT

13 enrolled